{"id":"https://openalex.org/W2912166265","doi":"https://doi.org/10.1111/ejh.13220","title":"Safety and effectiveness of mogamulizumab in relapsed or refractory adult T\u2010cell leukemia\u2010lymphoma","display_name":"Safety and effectiveness of mogamulizumab in relapsed or refractory adult T\u2010cell leukemia\u2010lymphoma","publication_year":2019,"publication_date":"2019-02-11","ids":{"openalex":"https://openalex.org/W2912166265","doi":"https://doi.org/10.1111/ejh.13220","mag":"2912166265","pmid":"https://pubmed.ncbi.nlm.nih.gov/30740787","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6850465"},"language":"en","primary_location":{"id":"doi:10.1111/ejh.13220","doi":"https://doi.org/10.1111/ejh.13220","is_oa":true,"landing_page_url":"https://doi.org/10.1111/ejh.13220","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13220","source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2912166265"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13220","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059167270","display_name":"Kenji Ishitsuka","orcid":"https://orcid.org/0000-0002-7030-497X","observed_orcids":["https://orcid.org/0000-0002-7030-497X"]},"institutions":[{"id":"https://openalex.org/I107139324","display_name":"Kagoshima University","ror":"https://ror.org/03ss88z23","country_code":"JP","type":"education","lineage":["https://openalex.org/I107139324"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Kenji Ishitsuka","raw_affiliation_strings":["Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan"],"raw_orcid":"https://orcid.org/0000-0002-7030-497X","affiliations":[{"raw_affiliation_string":"Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan","institution_ids":["https://openalex.org/I107139324"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047578901","display_name":"Satoshi Yurimoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I205823427","display_name":"Kyowa Kirin (Japan)","ror":"https://ror.org/000wej815","country_code":"JP","type":"company","lineage":["https://openalex.org/I205823427"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Satoshi Yurimoto","raw_affiliation_strings":["Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I205823427"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043670124","display_name":"Yukie Tsuji","orcid":"https://orcid.org/0000-0003-0813-433X","observed_orcids":["https://orcid.org/0000-0003-0813-433X"]},"institutions":[{"id":"https://openalex.org/I205823427","display_name":"Kyowa Kirin (Japan)","ror":"https://ror.org/000wej815","country_code":"JP","type":"company","lineage":["https://openalex.org/I205823427"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukie Tsuji","raw_affiliation_strings":["Pharmacovigilance and Quality Assurance Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance and Quality Assurance Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I205823427"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109067564","display_name":"Manabu Iwabuchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I205823427","display_name":"Kyowa Kirin (Japan)","ror":"https://ror.org/000wej815","country_code":"JP","type":"company","lineage":["https://openalex.org/I205823427"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Manabu Iwabuchi","raw_affiliation_strings":["Pharmacovigilance and Quality Assurance Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance and Quality Assurance Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I205823427"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062035100","display_name":"Takeshi Takahashi","orcid":"https://orcid.org/0000-0002-3898-5883","observed_orcids":["https://orcid.org/0000-0002-3898-5883"]},"institutions":[{"id":"https://openalex.org/I205823427","display_name":"Kyowa Kirin (Japan)","ror":"https://ror.org/000wej815","country_code":"JP","type":"company","lineage":["https://openalex.org/I205823427"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takeshi Takahashi","raw_affiliation_strings":["Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan"],"raw_orcid":"https://orcid.org/0000-0002-3898-5883","affiliations":[{"raw_affiliation_string":"Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I205823427"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036000764","display_name":"Kensei Tobinai","orcid":"https://orcid.org/0000-0002-7859-3227","observed_orcids":["https://orcid.org/0000-0002-7859-3227"]},"institutions":[{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kensei Tobinai","raw_affiliation_strings":["Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan","institution_ids":["https://openalex.org/I4405285273"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5059167270"],"corresponding_institution_ids":["https://openalex.org/I107139324"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":{"value":3300,"currency":"USD","value_usd":3300},"fwci":0.8724,"has_fulltext":true,"cited_by_count":26,"citation_normalized_percentile":{"value":0.67881575,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"102","issue":"5","first_page":"407","last_page":"415"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12159","display_name":"T-cell and Retrovirus Studies","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12159","display_name":"T-cell and Retrovirus Studies","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mogamulizumab","display_name":"mogamulizumab","score":1.0},{"id":"https://openalex.org/keywords/adult-t-cell-leukemia-lymphoma","display_name":"adult T-cell leukemia/lymphoma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.9290000200271606},{"id":"https://openalex.org/keywords/ccr4","display_name":"CCR4","score":0.8050000071525574},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8100000023841858},{"id":"https://openalex.org/keywords/skin-diseases","display_name":"skin diseases","score":0.7009999752044678},{"id":"https://openalex.org/keywords/infusion-related-reactions","display_name":"infusion reactions","score":0.9509999752044678},{"id":"https://openalex.org/keywords/infection","display_name":"infection","score":0.890999972820282},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7699999809265137},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9610000252723694},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.8330000042915344},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.7770000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8803439140319824},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6083806753158569},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5673830509185791},{"id":"https://openalex.org/C197636746","wikidata":"https://www.wikidata.org/wiki/Q7234359","display_name":"Postmarketing surveillance","level":3,"score":0.5560951828956604},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5016765594482422},{"id":"https://openalex.org/C2780815077","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Adult T-cell leukemia/lymphoma","level":4,"score":0.4964151978492737},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4936012029647827},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4779267907142639},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.41311872005462646},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3265402615070343},{"id":"https://openalex.org/C2776913467","wikidata":"https://www.wikidata.org/wiki/Q7667895","display_name":"T-cell leukemia","level":3,"score":0.09895330667495728},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015459","descriptor_name":"Leukemia-Lymphoma, Adult T-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015459","descriptor_name":"Leukemia-Lymphoma, Adult T-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1111/ejh.13220","doi":"https://doi.org/10.1111/ejh.13220","is_oa":true,"landing_page_url":"https://doi.org/10.1111/ejh.13220","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13220","source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6850465","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6850465","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6850465/pdf/EJH-102-407.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Eur J Haematol","raw_type":"Text"},{"id":"pmh:oai:europepmc.org:5821594","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6850465","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:30740787","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30740787","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of haematology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/ejh.13220","doi":"https://doi.org/10.1111/ejh.13220","is_oa":true,"landing_page_url":"https://doi.org/10.1111/ejh.13220","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13220","source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322359","display_name":"Kyowa Hakko Kirin","ror":"https://ror.org/0586k5242"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2912166265.pdf","grobid_xml":"https://content.openalex.org/works/W2912166265.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W79582184","https://openalex.org/W2009621572","https://openalex.org/W2039301421","https://openalex.org/W2057910076","https://openalex.org/W2071638887","https://openalex.org/W2102113607","https://openalex.org/W2109847786","https://openalex.org/W2113158224","https://openalex.org/W2121304964","https://openalex.org/W2158377087","https://openalex.org/W2166075265","https://openalex.org/W2317684406","https://openalex.org/W2336865896","https://openalex.org/W2518731718","https://openalex.org/W2583307538","https://openalex.org/W2597991926","https://openalex.org/W2604644782","https://openalex.org/W2624145351","https://openalex.org/W2754714487","https://openalex.org/W2794422241","https://openalex.org/W2884265149"],"related_works":["https://openalex.org/W2624145351","https://openalex.org/W2109160803","https://openalex.org/W4399436744","https://openalex.org/W2905627019","https://openalex.org/W2925056061","https://openalex.org/W2740885263","https://openalex.org/W2583307538","https://openalex.org/W2743566600","https://openalex.org/W2415435726","https://openalex.org/W2597991926"],"abstract_inverted_index":{"OBJECTIVE:":[0],"This":[1,169],"prospective,":[2],"observational,":[3],"postmarketing":[4,170],"surveillance":[5,171],"was":[6,74,152],"conducted":[7],"to":[8,43],"evaluate":[9],"the":[10,65,122,129,135,139,173,180],"safety":[11,66,174],"and":[12,80,84,115,134,145,156,165,175],"effectiveness":[13,123,157,176],"of":[14,47,96,141,177,182],"mogamulizumab,":[15],"an":[16],"anti-CC":[17],"chemokine":[18],"receptor":[19],"4":[20],"(CCR4)":[21],"monoclonal":[22],"antibody,":[23],"in":[24,36,58,91,190],"patients":[25,40,162,183],"with":[26,60,184],"CCR4-positive,":[27],"relapsed":[28],"or":[29,57],"refractory":[30],"(r/r)":[31],"adult":[32],"T-cell":[33],"leukemia-lymphoma":[34],"(ATL)":[35],"Japan.":[37],"METHOD:":[38],"All":[39],"were":[41,89,102,143,159],"scheduled":[42],"receive":[44],"intravenous":[45],"infusions":[46],"mogamulizumab":[48,72,178],"1.0":[49],"mg/kg":[50],"once":[51],"weekly":[52],"for":[53,179],"8":[54],"weeks,":[55],"alone":[56],"combination":[59],"other":[61],"modalities.":[62],"RESULTS:":[63],"In":[64,121],"analysis":[67,124],"population":[68,125],"comprising":[69,126],"572":[70],"patients,":[71,128,189],"therapy":[73,142],"started":[75],"between":[76,161],"May":[77],"29,":[78],"2012,":[79],"April":[81],"30,":[82],"2013,":[83],"adverse":[85],"drug":[86],"reactions":[87,110],"(ADRs)":[88],"reported":[90],"73.4%":[92],"(38.6%":[93],"serious":[94,107,113,119],"cases)":[95],"patients.":[97],"The":[98,148],"most":[99],"common":[100],"ADRs":[101],"skin":[103],"disorders":[104],"(33.2%":[105],"[10.8%":[106],"cases]),":[108,114],"infusion-related":[109],"(30.1%":[111],"[4.7%":[112],"infections":[116],"(22.0%":[117],"[14.7%":[118],"cases]).":[120],"523":[127],"best":[130],"overall":[131,150],"response":[132,136],"rate":[133,137],"at":[138],"end":[140],"57.9%":[144],"42.0%,":[146],"respectively.":[147],"median":[149],"survival":[151],"5.5":[153],"months.":[154],"Safety":[155],"results":[158],"similar":[160],"aged":[163],"\u226570":[164],"<70":[166],"years.":[167],"CONCLUSION:":[168],"confirmed":[172],"treatment":[181],"r/r":[185],"ATL,":[186],"including":[187],"elderly":[188],"clinical":[191],"practice.":[192]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2019-02-21T00:00:00"}